News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...
This segment is sponsored by Eli Lilly and Company.Social media is flooded with advertisments for popular obestiy medications ...
Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...
"Obesity is a complex, chronic condition that requires more than just treatment--it demands continuous medical education, empathy, and coordinated action across the healthcare ecosystem," said Dr.
Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...
The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results